Abstract: This disclosure relates to compounds of formulae I, II and III useful for degrading ITK via a ubiquitin proteolytic pathway. This disclosure also provides pharmaceutically acceptable compositions comprising said compounds, and methods of using the compositions in the treatment of various diseases, conditions, and/or disorders.

Abstract: A method for judging aging degree of insulation of a cable T-connector based on a dynamic heat source is provided. Specifically, a temperature rise verification test platform of the cable T-connector is constructed, and heating of a cable core is simulated by using a controllable heat source. Influence of different thermal conductivity of an insulation layer on internal and external temperature responses of the cable T-connector is studied, and the temperature rise test platform is constructed to simulate the temperature response of the outer skin of the cable T-connector under the same temperature change of the internal heat source and compare the temperature response of the outer skin of the cable T-connector in different states through experiments, so as to obtain the corresponding relationship between aging degree and heat transfer capacity.

Abstract: Provided herein are compounds for inhibiting and/or degrading IL-2 inducible T-cell kinase (ITK), compositions comprising the compounds, methods of making the same, and methods of their use for treating diseases or disorders including cancer, inflammatory, and autoimmune diseases.

Abstract: Disclosed is a method and system for grid connection management of renewable energy generation, the method comprises: obtaining operating condition data of a first power supply, a second power supply, a power grid, and a load in a preset period; establishing a first optimal control model according to the first condition data, and establishing a second optimal control model; monitoring grid connection management status of the first optimal control model and the second optimal control model; analyzing stability when the first optimal control model is switched to the second optimal control model. The beneficial effects of this disclosure are: completing the switch from the first optimal control model to the second optimal control model in the renewable energy generation grid connection management, which improves the smoothness of control model switching under different load conditions in the renewable energy generation process.

Abstract: Disclosed is a method and system for grid connection management of renewable energy generation, the method comprises: obtaining operating condition data of a first power supply, a second power supply, a power grid, and a load in a preset period; establishing a first optimal control model according to the first condition data, and establishing a second optimal control model; monitoring grid connection management status of the first optimal control model and the second optimal control model; analyzing stability when the first optimal control model is switched to the second optimal control model. The beneficial effects of this disclosure are: completing the switch from the first optimal control model to the second optimal control model in the renewable energy generation grid connection management, which improves the smoothness of control model switching under different load conditions in the renewable energy generation process.

Abstract: The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Abstract: The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Abstract: Provided herein are heterobifunctional compounds which find utility as modulators of targeted ubiquitination. Also provided herein are pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds, and compositions in the treatment of various diseases, conditions, or disorders.

Abstract: The present invention relates to compounds of formula (I) useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Abstract: The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Abstract: The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Abstract: The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein.

Abstract: The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein.

Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.

Abstract: The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein.

Abstract: The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein.

Abstract: The present invention provides polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein. The invention also provides methods of making and using these compounds to treat cancer, and particularly to treat hematological malignancies including multiple myeloma.

Abstract: The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.

Abstract: The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.

Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.